Navigation Links
Optimer Announces that the U.S. Food and Drug Administration's Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Date:4/5/2011

Optimer will host a conference call tomorrow at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss this announcement. To participate in the conference call, please dial (877) 280-7280 from the U.S., or (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Conference Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. 

About DIFICID™ (Fidaxomicin)

DIFICID™ (fidaxomicin) is a new antibiotic with a novel mechanism of action, which inhibits the bacterial enzyme RNA polymerase, resulting in the rapid killing of C. difficile. The narrow-spectrum profile of DIFICID eradicates C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics used to treat CDI, metronidazole and vancomycin, have been shown to disrupt the gut flora. DIFICID facilitates the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence rates. In two Phase 3 trials for the treatment of CDI, DIFICID was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  DIFICID also demonstrated statistically significant reduction in recurrences and an increase in global cure rate, defined as cure without recurrence. Importantly, DIFICID reduced the risk of recurrence by 47% compared to vancomycin. The New England Journal of Medicine has published results from the first Phase 3 trial in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," which
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... Texas , March 4, 2015 ... II pilot study in patients with moderate to ... Dermatology. The open-label Phase II trial evaluated the ... monoclonal antibody that targets interleukin-1 alpha (IL-1a). IL-1a ... inflammatory cells present in skin lesions. The Company ...
(Date:3/4/2015)... Pa. , March 4, 2015  Results of ... 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin ... poster session at the 32 nd Annual Miami ... study, conducted by Moshe Papa , MD, FACS, ... at Tel Aviv University, reports an analysis of MarginProbe,s ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
(Date:3/5/2015)... Southlake, TX (PRWEB) March 05, 2015 ... an in-office, non-surgical treatment for OB-GYNs and Urogynecologists. ... system, used for non-surgical dermatological application in aesthetics ... pleased to have a non-invasive, in-office procedure, and ... for women who want results without surgery. ThermiVa ...
(Date:3/5/2015)... Building on its commitment to provide ... The Academy of Oncology Nurse & Patient Navigators (AONN+) ... voice ™ (CONQUER ™). , “Cancer has ... and their loved ones each year,” says Pam Rattananont ... ever, there is a need in the oncology space ...
(Date:3/4/2015)... MyCpapStore.com, an online provider of CPAP equipment ... quality products designed to remedy the problem of snoring. ... merchandise from name-brand manufacturers, giving its customers access to ... Sleep apnea is a common condition affecting people of ... restricted airflow. The CPAP (continuous positive airway pressure) machine ...
(Date:3/4/2015)... Vegas, NV (PRWEB) March 04, 2015 In ... as the fight that is the main event. For ... and that fight will be for the UFC Featherweight Championship. ... the brash, often out-spoken native of Ireland, Conor “Notorious” McGregor. ... MGM Grand Garden Arena in Las Vegas, NV. , When ...
(Date:3/4/2015)... Dr. Christopher Asandra, M.D., Founder and Chief ... lamented the FDA’s recent decision to issue a ... that FDA’s conclusions are not supported by science, and ... testosterone deficiency. , “The FDA appears to have developed ... said Dr. Asandra. “There is not nearly enough evidence ...
Breaking Medicine News(10 mins):Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 2Health News:ThermiHealth Announces the Introduction of ThermiVa in North America to OB-GYNs 3Health News:The Academy of Oncology Nurse & Patient Navigators Launches CONQUER: the patient voice™ to Help Meet the Informational Needs of Patients with Cancer 2Health News:Sleep Apnea Machines CPAP and BiPap Machines Now Available for Sale 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 2Health News:Cheap UFC 189 Tickets: Jose Aldo vs. Conor McGregor UFC 189 Ticket Prices Slashed by Ticket Down for Featherweight Title 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2
... for Airlift of ... Medical Supplies, ... Myanmar earlier today to assess the,crisis situation and continue with efforts ... medicines and medical,supplies to Yangon., "AmeriCares is working closely with ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading ... aesthetic treatment systems, today announced that it has,received ... Administration (KFDA),for its flagship Accolade(TM) workstation for the ... quarter of 2008, the Accolade is the third,Cynosure ...
... DIEGO, May 9 Summary: With the recent ... and leaving over a,million people homeless, the need ... and Steve Jones have launched the Myanmar,Challenge, a ... hopes of filling the need as much as ...
... in Virginia to,Envision a Bold Future for Military & ... As the war in Iraq,enters its fifth year and ... approach the 30,000 mark, a diverse coalition of military,and ... help,bereaved families and wounded veterans. In some cases, they ...
... artery-opening devices , , FRIDAY, May 9 (HealthDay News) -- ... tools that have extended the lives of millions of ... arteries. , The wire metal mesh tubes, when inserted ... and ensure a constant supply of blood to the ...
... 9 UNFPA, the United,Nations Population Fund, is ... concerns of cyclone-affected populations, particularly women,and girls, in ... is being sought as part of a joint ... today. Tens of thousands of pregnant women,made homeless ...
Cached Medicine News:Health News:AmeriCares Relief Worker Arrives in Myanmar 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 2Health News:Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval 3Health News:New Web Site to Raise Awareness for the Myanmar Crisis Has Lofty Goals 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Drug-Coated Stents Still Spark Debate 2Health News:Drug-Coated Stents Still Spark Debate 3Health News:$3 Million Requested by UNFPA to Help Women and Girls Displaced by Myanmar Cyclone 2
2.5V Incandescent source, 3X magnification, pocket-sized....
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
Pocket-sized instrument with fiber optic illumination. Swivelling viewing window with 3X magnification....
Medicine Products: